Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)

Stock Information for ProPhase Labs Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ProPhase Labs Inc.

Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights
Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024
Tonix Pharmaceuticals to Present at BIO-Europe® 2024
Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA)
Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.